Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VRVWG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Tra-25-4
|
|||||
| Synonyms |
Tra-25-4
Click to Show/Hide
|
|||||
| Organization |
PINOTBIO, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PBX-7014
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
25‐4
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.1192 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 34.5 nM | Low HER2 expression (HER2+) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 128.8 nM | Negative HER2 expression (HER2-) | ||
| Method Description |
Cell viability analysis of MDA-MB-453 (HER2+++) cell line, FaDu (HER2+) cell line and MDA-MB-468 (HER2-) cell line in vitro.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||